Possibilities of non-hormonal therapy in the correction of manifestations of climacteric syndrome
https://doi.org/10.14341/brh12775
Abstract
Vasomotor symptoms during the menopausal transition occur in 80% of women and can last for years, which seriously reduces the quality of life. Typical complaints of patients include hot flashes, increased sweating, and sleep disorders. Treatment and correction of menopausal transition problems is an important task for an obstetrician-gynecologist. Today, menopausal hormone therapy is the gold standard in stopping hot flashes and preventing osteoporosis, but it has serious limitations and contraindications. For those categories of women who cannot or do not want to take hormonal drugs due to personal preferences, non-hormonal alternative methods should be offered. The article provides an overview of possible options for drug and non-drug interventions, and discusses evidence of the effectiveness and safety of alternative means, including dietary correction using a complex of herbal components and vitamins Estrovel in order to prevent the pathological course of menopause and prevent age-associated conditions. The literature search was carried out in Russian (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases. Free access to the full text of publications was preferred. The selection of sources was prioritized by the period from 2018 to 2025, however, the list of references includes works dated earlier.
About the Authors
E. N. Andreeva
Endocrinology Research Centre Russia; Russian University of medicine
Russian Federation
Competing Interests:
Russian Federation
Elena N. Andreeva - MD, PhD, professor.
Moscow
Competing Interests:
none
Yu. S. Absatarova
Endocrinology Research Centre Russia
Russian Federation
Competing Interests:
Russian Federation
Yulia S. Absatarova - MD, PhD.
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
none
References
1. Yureneva SV, Il’ina LM, Ebzieva ZH. Menopauzal’nye vazomotornye simptomy: social’nye aspekty, dinamika, kardiometabolicheskie riski i vozmozhnosti gormonal’noj terapii. Akusherstvo i ginekologiya. 2019;1:26-32 (In Russ.) doi: https://doi.org/10.18565/aig.2019.L26-32
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. doi: https://doi.org/10.1001/jama.288.3.321
3. Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med. 2020;382(5):446–55. doi: https://doi.org/10.1056/NEJMcp1714787
4. Murtaza F, Shirreff L, Huang LN, et al. Quality and readability of online health information on menopausal hormone therapy in Canada: what are our patients reading? Menopause. 2021;29:54-62. doi: https://doi.org/10.1097/GME.0000000000001881
5. “The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. doi: https://doi.org/10.1097/GME.0000000000002200
6. Rossijskoe obshhestvo akusherov-ginekologov. Klinicheskie rekomendacii. Menopauza i klimaktericheskoe sostoyanie u zhenshchiny. 2021. (In Russ.) https://cr.minzdrav.gov.ru/view-cr/117_2?ysclid=mb7ygm319s416903155
7. Strelow B, O’Laughlin D, Anderson T, et al. Menopause Decoded: What’s Happening and How to Manage It. J Prim Care Community Health. 2024;15:21501319241307460. doi: https://doi.org/10.1177/21501319241307460
8. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102. doi: https://doi.org/10.1016/S0140-6736(23)00085-5
9. Besong C, Philippeaux S, Bham A, et al. Managing Menopause: The Evolving Role of Estrogens, Selective Serotonin Reuptake Inhibitors, and Phytoestrogens in Balancing Hormonal Fluctuations. Cureus. 2024;16(9):e70440. doi: https://doi.org/10.7759/cureus.70440
10. Chen MN, Lin CC, Liu CF. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. Climacteric. 2015;18:260–269. doi: https://doi.org/10.3109/13697137.2014.966241
11. Reed SD, Lampe JW, Qu C, et al. Self-reported menopausal symptoms in a racially diverse population and soy food consumption. Maturitas. 2013;75(2):152–158. doi: https://doi.org/10.1016/j.maturitas.2013.03.003
12. Xiang Z, Ma B, Pei X, et al. Mechanism of action of genistein on breast cancer and differential effects of different age stages. Pharm Biol. 2025;63(1):141-155. doi: https://doi.org/10.1080/13880209.2025.2469607
13. Mukund V, Behera SK, Alam A, et al. Molecular docking analysis of nuclear factor-κB and genistein interaction in the context of breast cancer. Bioinformation. 2019;15(1):11–17. doi: https://doi.org/10.6026/97320630015011
14. Chen M, Li S, Srinivasasainagendra V, et al. Maternal soybean genistein on prevention of later-life breast cancer through inherited epigenetic regulations. Carcinogenesis. 2022;43(3):190–202. doi: https://doi.org/10.1093/carcin/bgac009
15. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: https://doi.org/10.3322/caac.21660
16. Wan MLY, Co VA, El-Nezami H. Endocrine disrupting chemicals and breast cancer: a systematic review of epidemiological studies. Crit Rev Food Sci Nutr. 2022:62(24):6549–6576. doi: https://doi.org/10.1080/10408398.2021.1903382
17. Shu XO, Zheng Y, Cai H, et al. Soy food intake and breast cancer survival. JAMA. 2009;302(22):2437-2443. doi: https://doi.org/10.1001/jama.2009.1783
18. Chen LR, Ko NY, Chen KH. Isoflavone Supplements for Menopausal Women: A Systematic Review. Nutrients. 2019;11(11):2649. doi: https://doi.org/10.3390/nu11112649
19. Simon JA, Davis SR, Lindén Hirschberg A, et al. State of the art in menopause: current best practice approaches from the IMS World Congress 2024, Melbourne. Climacteric. 2025;28(2):98-103. doi: https://doi.org/10.1080/13697137.2025.2457993
20. Thurston RC, Aslanidou Vlachos HE, Derby CA, et al. Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN. J Am Heart Assoc. 2021;10(3):e017416. doi: https://doi.org/10.1161/JAHA.120.017416
21. Blanco Mejia S, Messina M, Li SS, et al. A meta-analysis of 46 studies identified by the FDA demonstrates that soy protein decreases circulating LDL and total cholesterol concentrations in adults. J. Nutr. 2019;149(6):968–981. doi: https://doi.org/10.1093/jn/nxz020
22. Naghshi S, Tutunchi H, Yousefi M, et al. Soy isoflavone intake and risk of cardiovascular disease in adults: A systematic review and dose-response meta-analysis of prospective cohort studies. Crit Rev Food Sci Nutr. 2024;64(18):6087-6101. doi: https://doi.org/10.1080/10408398.2022.2163372
23. Viscardi G, Back S, Ahmed A, et al. Effect of Soy Isoflavones on Measures of Estrogenicity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2025;16(1):100327. doi: https://doi.org/10.1016/j.advnut.2024.100327
24. Kuznecova IV, Vojchenko NA, Kirillova MYu. Kachestvo zhizni i kardiovaskulyarnyj risk u zhenshchin v periodah menopauzal’nogo perekhoda i postmenopauzy. Medicinskij alfavit. 2020;(4):39-45 (In Russ.)
25. Tatarova NA, Ajrapetyan MS, Zhigalova EV. Startovaya terapiya klimaktericheskogo sindroma perekhodnogo menopauzal’nogo perioda. RMZh. Mat’ i ditya. 2017; 25(2): 98–103 (In Russ.)
26. Shi V, Morgan EF. Estrogen and estrogen receptors mediate the mechanobiology of bone disease and repair. Bone. 2024;188:117220. doi: https://doi.org/10.1016/j.bone.2024.117220
27. Aaseth JO, Finnes TE, Askim M, et al. The Importance of Vitamin K and the Combination of Vitamins K and D for Calcium Metabolism and Bone Health: A Review. Nutrients. 2024;16(15):2420. doi: https://doi.org/10.3390/nu16152420
28. Zoch ML, Clemens TL, Riddle RC. New insights into the biology of osteocalcin. Bone. 2016;82:42–49. doi: https://doi.org/10.1016/j.bone.2015.05.046
29. Feskanich D, Weber P, Willett WC, et al. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr. 1999;69(1):74-9. doi: https://doi.org/10.1093/ajcn/69.1.74
30. Torbergsen AC, Watne LO, Wyller TB, et al. Vitamin K1 and 25 (OH) D are independently and synergistically associated with a risk for hip fracture in an elderly population: A case control study. Clin. Nutr. 2015;34:101–106. doi: https://doi.org/10.1016/j.clnu.2014.01.016
31. Baez-Gonzalez AS, Carrazco-Carrillo JA, Figueroa-Gonzalez G, et al. Functional effect of indole-3 carbinol in the viability and invasive properties of cultured cancer cells. Biochem Biophys Rep. 2023;35:101492. doi: https://doi.org/10.1016/j.bbrep.2023.101492
32. Brandi G, Paiardini M, Cervasi B, et al. A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res. 2003;63:4028–4036
33. Seyoum Tola F. The concept of folic acid supplementation and its role in prevention of neural tube defect among pregnant women: PRISMA. Medicine (Baltimore). 2024;103(19):e38154. doi: https://doi.org/10.1097/MD.0000000000038154
34. Thornburgh S, Gaskins AJ. B vitamins, polycystic ovary syndrome, and fertility. Curr Opin Endocrinol Diabetes Obes. 2022;29(6):554-559. doi: https://doi.org/10.1097/MED.0000000000000773
35. Ismail S, Eljazzar S, Ganji V. Intended and Unintended Benefits of Folic Acid Fortification-A Narrative Review. Foods. 2023;12(8):1612. doi: https://doi.org/10.3390/foods12081612
36. Kaye AD, Jeha GM, Pham AD, et al. Folic Acid Supplementation in Patients with Elevated Homocysteine Levels. Adv. Ther. 2020;37:4149–4164. doi: https://doi.org/10.1007/s12325-020-01474-z
37. Fu P, Gibson CJ, Mendes WB, et al. Anxiety, depressive symptoms, and cardiac autonomic function in perimenopausal and postmenopausal women with hot flashes: a brief report. Menopause. 2018;25:12:1470-1475. doi: https://doi.org/10.1097/GME.0000000000001153
38. Bromberger JT, Kravitz HM, Chang Y, et al. Does risk for anxiety increase during the menopausal transition? Study of Women’s Health Across the Nation. Menopause. 2013;20:5:488-495. doi: https://doi.org/10.1097/GME.0b013e3182730599
39. Khalili P, Asbaghi O, Aghakhani L, et al. The effects of folic acid supplementation on depression in adults: A systematic review and meta-analysis of randomized controlled trials. Nutr. Food Sci. 2023;53:521–534. doi: https://doi.org/10.1108/NFS-02-2022-0043
40. Maki PM, Jaff NG. Brain fog in menopause: a healthcare professional’s guide for decision-making and counseling on cognition. Climacteric. 2022;25(6):570–578. doi: https://doi.org/10.1080/13697137.2022.2122792
41. Islam MT, Al Shamsh Prottay A, Bhuia MS, et al. Memory-Enhancing Effects of Daidzin, Possibly Through Dopaminergic and AChEergic Dependent Pathways. J Nutr. 2025:S0022-3166(25)00269-X. doi: https://doi.org/10.1016/j.tjnut.2025.04.024
42. Uddenberg ER, Safwan N, Saadedine M, et al. Menopause transition and cardiovascular disease risk. Maturitas. 2024;185:107974. doi: https://doi.org/10.1016/j.maturitas.2024.107974
43. Thurston RC, Chang Y, Kline CE, et al. Trajectories of sleep over midlife and incident cardiovascular disease events in the Study of Women’s Health Across the Nation. Circulation. 2024;149:7: 545-555. doi: https://doi.org/10.1161/CIRCULATIONAHA.123.066491
44. Martins FO, Conde SV. Gender differences in the context of obstructive sleep apnea and metabolic diseases. Front Physiol. 2021;12:792633. doi: https://doi.org/10.3389/fphys.2021.792633
45. Maffei ME. 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology. Int J Mol Sci. 2020;22(1):181. doi: https://doi.org/10.3390/ijms22010181
46. Cerqueira RO, Frey BN, Leclerc E, et al. Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health. 2017;20:713–719. doi: https://doi.org/10.1007/s00737-017-0791-0
47. Höller M, Steindl H, Abramov-Sommariva D, et al. Use of Vitex agnus-castus in patients with menstrual cycle disorders: a single-center retrospective longitudinal cohort study. Arch Gynecol Obstet. 2024 May;309(5):2089-2098. doi: https://doi.org/10.1007/s00404-023-07363-4
48. Soleimany Z, Siadat F, Farhadi M, et al. Improvement of ovarian function in a premature ovarian failure mouse model using Vitex agnus-castus extract. JBRA Assist Reprod. 2025;29(1):117-126. doi: https://doi.org/10.5935/1518-0557.20240101
49. Kumari R, Thakur A, Thakur P, et al. An Update on the Nutritional and Therapeutic Potential of Dioscorea oppositifolia. Food Sci Nutr. 2025;13(5):e70179. doi: https://doi.org/10.1002/fsn3.70179
50. Lu J, Wong RN, Zhang L, et al. Comparative Analysis of Proteins with Stimulating Activity on Ovarian Estradiol Biosynthesis from Four Different Dioscorea Species in vitro Using Both Phenotypic and Target-based Approaches: Implication for Treating Menopause. Appl Biochem Biotechnol. 2016;180(1):79-93. doi: https://doi.org/10.1007/s12010-016-2084-x
Review
For citations:
Andreeva E.N., Absatarova Yu.S. Possibilities of non-hormonal therapy in the correction of manifestations of climacteric syndrome. Bulletin of Reproductive Health. 2025;4(3):20-27. (In Russ.) https://doi.org/10.14341/brh12775
Views:
23
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
